Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAPSone as a Second-line Option in Adult Immune Thrombocytopenia
NCT02627417Phase 3Unknown
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Dec 2015
- Primary completion
- May 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dapsone in immune thrombocytopenia (ITP) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Overall Response Rate at 52 weeks. Status: unknown.
02
Drugs
dapsone
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT02627417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02627417.